Michael Bergman

Michael Bergman completed his medical studies at the Medical University of Vienna (MUV), followed by a four-year training in the genetic engineering of viruses at the Department of Microbiology at the Mount Sinai Medical School in New York, where he worked. After that, he specialized in surgery and is board certified as a general, visceral, and robotic colorectal surgeon. Michael teaches at the medical school, doctoral studies, and postgraduate courses for surgeons at the MUV.

Michael is a member of the Austrian Society of Surgery and the European Association for Cancer Research – EACR among others. He is a deputy editor of the Molecular Therapy Oncolytics and Cell Press journals and reviewer for the Journal for Immunotherapy of Cancer, Journal of Translational Medicine, Journal of Molecular Medicine, Molecular Cancer journal, and the Cancer UK fund. Michael published a large number of well-cited scientific articles. He was also a principal investigator in several translational medicine programs focused on various aspects of cancer biology and treatment.

His research is focused on tumor immunology, cancer immunotherapy, oncolytic influenza A virus, and inflammatory bowel diseases with a particular emphasis on investigating the role of chemotherapy or radiotherapy) induced changes in the solid tumor-immune microenvironment. The main aim is to develop novel cancer immunotherapy concepts and optimize cancer treatment using a rational combined approach.

Through his expertise in the genetic engineering of the influenza A virus, Michael and his team developed the first oncolytic influenza A virus. Currently, he works on optimizing the viral vectors and their production to facilitate a routine clinical application.